# Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab

> **NCT04320602** · PHASE4 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **BIOLOGICAL:** Eculizumab
- **BIOLOGICAL:** Ravulizumab

## Key facts

- **NCT ID:** NCT04320602
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-14
- **Primary completion:** 2022-12-20
- **Final completion:** 2022-12-20
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04320602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04320602, "Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04320602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*